Understanding how the brain learns to control hand movements
Official title: Neural Basis of Sensory Learning: Brain Regions
Run by Indiana University · NCT05079516 · Data updated 2026-11-12
This study is testing how the brain learns to control hand movements in different situations to help improve rehabilitation for people with brain injuries.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Indiana University Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Bloomington, Indiana) |
| Status | Recruiting |
| Started | October 26, 2021 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | May 4, 2026 |
| Trial ID | NCT05079516 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are right-handed individuals aged 18-45 without neurological impairments.
✕Probably not a fit
Patients outside the age range, left-handed individuals, or those with existing neurological conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to explore the interaction between sensory and motor areas of the brain in maintaining accurate hand movements, particularly under varying environmental conditions. By examining how the brain compensates for challenges like changes in viscosity and visual distortions, the researchers hope to uncover mechanisms that could enhance rehabilitation techniques for individuals with brain lesions. The study will utilize theta burst transcranial magnetic stimulation as an intervention to assess these processes in right-handed adults aged 18-45. Insights gained may lead to tailored rehabilitation strategies for those with sensory and motor deficits.
Why it matters
Potential benefit: If successful, this research could lead to improved rehabilitation techniques for patients recovering from brain injuries or strokes.
How similar studies have gone: While the specific approach of this study is novel, similar studies have shown promise in understanding sensorimotor learning and rehabilitation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Potential subjects must be between the ages of 18-45 years old and right-handed. Aging has been shown to affect the morphology of sensory and motor nerves, conduction velocities of nerves, and number of motor neurons in the spinal cord; to avoid these confounding factors we will only examine younger-to middle-aged adults. * There are differences in cortical function and corticospinal projections such that testing the right arm of a right-handed individual is not necessarily equivalent to testing the left arm of a left-handed individual. To eliminate this confound, we will only test right-handed individuals. All these factors will be determined with the initial screening questions. * Covid has been found to have neurological effects in some people, but mostly the effects on sensorimotor control and neurophysiology are unknown. So we want to reduce the chances of inadvertently testing subjects who have covid. We will therefore only include individuals who are fully vaccinated (2+ weeks past their final vaccine dose) or have a negative Covid test within 4 days of testing. We will further only include individuals who report being free of Covid symptoms in week preceding testing. Exclusion Criteria: 1. Determined with initial screening questions, pre-enrollment: Potential subjects will be excluded for current vision problems, other than needing glasses or contacts. Subjects will also be excluded if they currently suffer from frequent severe headaches, glaucoma, heart or respiratory disease, hypertension, psychiatric conditions, or learning or attention conditions. They will also be excluded for current or past: visual, hearing, or balance impairments; stroke, seizure/epilepsy (including family history), or severe head trauma; fainting; or diabetes. Subjects will be excluded for metal implants in the head other than titanium; cochlear implants; implanted neurostimulator; cardiac pacemaker; intracardiac lines; or a medication infusion device. Because TMS does not penetrate deeply into the head, we cannot test subjects whose hair does not permit contact between the TMS coil and the scalp. We will therefore exclude subjects with dreadlocks, weaves, or hair extensions. To protect the data from extraneous peripheral influences, we will also exclude subjects who have had serious injury to the bones, joints, or muscles of either hand or arm, and have not fully recovered. For the purpose of this study, "fully recovered" means they no longer notice any pain, weakness, or loss of sensation in the injured area, and have no mobility limitations. For the validity of our data, we will exclude subjects taking medications or drugs that are known to affect cortical excitability and possibly seizure risk in an rTMS study. These medications/drugs are (Rossi et al., 2009): imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma-hydroxybutyrate (GHB), theophylline, mianserin, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, reboxetine, venlafaxine, duloxetine, bupropion, mirtazapine, fluphenazine, pimozide, haloperidol, olanzapine, quetiapine, aripiprazole, ziprasidone, risperidone, chloroquine, mefloquine, imipenem, penicillin, ampicillin, cephalosporins, metronidazole, isoniazid, levofloxacin, cyclosporin, chlorambucil, vincristine, methotrexate, cytosine arabinoside, BCNU, lithium, anticholinergics, antihistamines, sympathomimetics. 2. Determined on each day of TMS testing: Potential subjects will be invited to reschedule if they would otherwise be eligible (according to the initial screening), but the day of testing have drunk more than 3 units of alcohol or taken other recreational drugs in the 24 hour period prior to testing; have had more than 3 cups of coffee in the last hour; are sleep deprived (\<4 hours sleep the previous night); or have participated in another brain stimulation experiment the same day. These are standard in the TMS literature to protect the validity of the data and keep seizure risk minimal. In addition, we will invite invite subjects to reschedule if they have any of the common Covid symptoms within the last week and if they haven't been fully vaccinated or obtained a negative Covid test within the past 4 days. If they don't believe they can meet these criteria on another date, they will be excluded. 3. Determined during the Familiarization session. After giving their consent, participants may be excluded during or after the familiarization session if they are unable to perform the reaching task or follow instructions, or if their TMS stimulation parameters cannot be reliably determined by the experimenter, or if TMS is not well tolerated.
Where it's running
-
Indiana University Bloomington
Bloomington, Indiana, United States Recruiting
Study contacts
- Principal investigator: William P Hetrick, PhD — Indiana University, Bloomington
- Study coordinator: William P Hetrick, PhD
- Email: whetrick@iu.edu
- Phone: 8128552620
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating the effects of serotonin receptor modulation on brain function
This study tests how two different substances, psilocybin and ketanserin, affect brain function and mood in healthy volunteers to better understand their impact on the brain.
-
Goal setting in a school-based sport program for rural middle schoolers
This project tests whether a 6-week goal-setting program embedded in a school sport program can boost physical activity among 6th–7th graders in two rural Indiana middle schools.
-
Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma
In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.
-
Hydroxychloroquine for AIMSS in breast cancer patients on aromatase inhibitors
This study tests whether hydroxychloroquine can reduce joint pain in people with breast cancer who are taking aromatase inhibitors and have AIMSS.
-
New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV
This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.
-
Sensor-enabled ankle brace for gait and balance testing in adults
Researchers are testing a modified ankle brace with built-in sensors to see if it accurately measures gait and balance compared with standard equipment in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.